Clinical Trial Update: Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX [Phase 3]

View source ↗

Summary

An update on the ongoing Phase 3 long-term safety and efficacy study of fitusiran in patients with Hemophilia A or B, including those with inhibitors to factor …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Fitusiran (fitusiran)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Hemophilia | Phase 3 | Status: ACTIVE_NOT_RECRUITING